READ THE FULL IMNN RESEARCH REPORT
Business Update
First Patient Dosed in Phase 3 OVATION 3 Trial
On July 30, 2025, Imunon, Inc. (NASDAQ:IMNN) announced that the first patient has been dosed in the Phase 3 OVATION 3 trial of IMNN-001 for the treatment of women with newly diagnosed advanced ovarian cancer.
The OVATION 3 trial will enroll patients with either Stage IIIc or IV advanced ovarian cancer who will be randomized to receive neoadjuvant chemotherapy (NACT), interval debulking surgery, and adjuvant chemotherapy with or without IMNN-001. The first cohort of patients will focus on those who are positive for homologous recombination deficiency (HDR) and will also be administered poly ADP-ribose polymerase (PARP) inhibitor therapy as part of standard-of-care (SOC) maintenance therapy. The primary endpoint is overall survival (OS), with secondary endpoints evaluating surgical response score, chemotherapy response score, clinical response (ORR), and time to second-line treatment. The following slide provides an overview of the statistical plan for the trial. Final analysis of the trial will occur after 135 events have occurred, however two interim analyses are planned following 68 and 101 events, representing 50% and 75% of the planned final event total, respectively.
The study was designed to maximize operational flexibility as it is powered at >95% to examine either a 250-patient cohort of HRD positive individuals or a 500-patient all-comers population. The company has decided to initially focus on the HRD positive subgroup as it potentially offers cost savings of up to 40% and could lead to a data readout up to two years earlier. HRD positive patients constitute approximately 50% of the advanced ovarian cancer population, thus it is still a sizeable market opportunity. The company is still committed to examining IMNN-001 in a broader population of patients, however that may need to come at a later time when sufficient financing is available to conduct that study. The decision to target the HRD positive subgroup will help to conserve cash, targeting the highest probability subgroup, and delivering results as quickly as possible. In summary, this design allows Imunon to decrease the initial investment required, decrease the timeline to data readout, and allows the company to be more aggressive with site engagement.
Phase 2 OVATION 2 Data Presented at ASCO
During the second quarter of 2025, results from the Phase 2 OVATION 2 trial were presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting and simultaneously published in the peer-reviewed journal Gynecologic Oncology. The data showed the following:
- Patients in the intent-to-treat (ITT) population that received IMNN-001 plus standard-of-care (SoC) neoadjuvant/adjuvant chemotherapy (N/ACT) had a median increase in overall survival (OS) of 13 months compared to patients who received only SoC N/ACT alone (46 vs. 33 months, HR=0.69).
- For patients also receiving treatment with poly ADP-ribose polymerase (PARP) inhibitors, the mean OS has not yet been reached in the IMNN-001 arm after more than five years compared to 37 months in the control arm (HR=0.38).
- For women who were positive for homologous recombination deficiency (HRD+), including BRCA1 and BRCA2 mutations, the HR was 0.42.
- In addition to an increase in OS, for the ITT population patients treated with IMNN-001 along with SoC N/ACT showed a median 3-month increase in progression-free survival (PFS) compared to SoC N/ACT alone (14.9 months vs. 11.9 months, HR=0.79).
- For patients also receiving PARP inhibitors, there was an 11.7-month increase in PFS for those treated with IMNN-001 and SoC N/ACT compared to SoC N/ACT alone (33.8 months vs. 22.1 months, HR=0.8).
- IMNN-001 was well tolerated, with the most common adverse events (AEs) including abdominal pain, nausea, and vomiting. Importantly, there were no reports of cytokine release syndrome, systemic toxicity, or serious immune-related AEs.
If these results are replicated in the Phase 3 OVATION 3 trial, it may result in transforming the standard of care for advanced ovarian cancer patients, where no improvement in OS has been reported in more than 25 years.
Financial Update
On August 5, 2025, Imunon announced financial results for the second quarter of 2025. As expected, the company did not report any revenue during the second quarter of 2025. R&D expenses in the second quarter of 2025 were $1.2 million compared to $2.8 million in the second quarter of 2024. The decrease was primarily due to lower costs associated with the OVATION 2 study, the Phase 1 PlaCCine DNA vaccine trial, and the development of the PlaCCine DNA vaccine technology. G&A expenses in the second quarter of 2025 were $1.5 million compared to $2.2 million for the first quarter of 2024. The decrease was primarily due to lower employee-related and legal expenses.
As of June 30, 2025, Imunon had approximately $4.7 million in cash and cash equivalents. During July 2025 the company received $3.1 million in net proceeds from the exercise of warrants and sales under the ATM facility. We estimate the company has sufficient capital to fund operations into the fourth quarter of 2025, however substantial additional capital will be necessary to complete the OVATION 3 trial. Following a 1-for-15 reverse split enacted on July 23, 2025, as of August 1, 2025 Imunon has approximatley 2.2 million common shares outstanding. The company also recently announced a stock dividend, whereby 0.15 shares of common stock will be granted per each share of common stock outstanding. This will result in the issuance of approximately 448,000 shares, which are payable to holders of record as of August 7, 2025. When factoring in stock options, warrants, and the stock dividend we estimate the company has a fully diluted share count of approximately 3.8 million.
Conclusion
We’re excited to see that Imunon has gotten the first patient dosed in the OVATION 3 trial and we look forward to updates from the company as the trial advances, including its efforts to secure financing for the study. The stock dividend is a nice reward for shareholders and shows the company is committed to making sure its interests align with those of current shareholders. We have adjusted our model to account for the reverse split and the July 2025 financing, and our valuation now stands at $45 per share.
Business Update
First Patient Dosed in Phase 3 OVATION 3 Trial
On July 30, 2025, Imunon, Inc. (NASDAQ:IMNN) announced that the first patient has been dosed in the Phase 3 OVATION 3 trial of IMNN-001 for the treatment of women with newly diagnosed advanced ovarian cancer.
The OVATION 3 trial will enroll patients with either Stage IIIc or IV advanced ovarian cancer who will be randomized to receive neoadjuvant chemotherapy (NACT), interval debulking surgery, and adjuvant chemotherapy with or without IMNN-001. The first cohort of patients will focus on those who are positive for homologous recombination deficiency (HDR) and will also be administered poly ADP-ribose polymerase (PARP) inhibitor therapy as part of standard-of-care (SOC) maintenance therapy. The primary endpoint is overall survival (OS), with secondary endpoints evaluating surgical response score, chemotherapy response score, clinical response (ORR), and time to second-line treatment. The following slide provides an overview of the statistical plan for the trial. Final analysis of the trial will occur after 135 events have occurred, however two interim analyses are planned following 68 and 101 events, representing 50% and 75% of the planned final event total, respectively.
The study was designed to maximize operational flexibility as it is powered at >95% to examine either a 250-patient cohort of HRD positive individuals or a 500-patient all-comers population. The company has decided to initially focus on the HRD positive subgroup as it potentially offers cost savings of up to 40% and could lead to a data readout up to two years earlier. HRD positive patients constitute approximately 50% of the advanced ovarian cancer population, thus it is still a sizeable market opportunity. The company is still committed to examining IMNN-001 in a broader population of patients, however that may need to come at a later time when sufficient financing is available to conduct that study. The decision to target the HRD positive subgroup will help to conserve cash, targeting the highest probability subgroup, and delivering results as quickly as possible. In summary, this design allows Imunon to decrease the initial investment required, decrease the timeline to data readout, and allows the company to be more aggressive with site engagement.
Phase 2 OVATION 2 Data Presented at ASCO
During the second quarter of 2025, results from the Phase 2 OVATION 2 trial were presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting and simultaneously published in the peer-reviewed journal Gynecologic Oncology. The data showed the following:
- Patients in the intent-to-treat (ITT) population that received IMNN-001 plus standard-of-care (SoC) neoadjuvant/adjuvant chemotherapy (N/ACT) had a median increase in overall survival (OS) of 13 months compared to patients who received only SoC N/ACT alone (46 vs. 33 months, HR=0.69).
- For patients also receiving treatment with poly ADP-ribose polymerase (PARP) inhibitors, the mean OS has not yet been reached in the IMNN-001 arm after more than five years compared to 37 months in the control arm (HR=0.38).
- For women who were positive for homologous recombination deficiency (HRD+), including BRCA1 and BRCA2 mutations, the HR was 0.42.
- In addition to an increase in OS, for the ITT population patients treated with IMNN-001 along with SoC N/ACT showed a median 3-month increase in progression-free survival (PFS) compared to SoC N/ACT alone (14.9 months vs. 11.9 months, HR=0.79).
- For patients also receiving PARP inhibitors, there was an 11.7-month increase in PFS for those treated with IMNN-001 and SoC N/ACT compared to SoC N/ACT alone (33.8 months vs. 22.1 months, HR=0.8).
- IMNN-001 was well tolerated, with the most common adverse events (AEs) including abdominal pain, nausea, and vomiting. Importantly, there were no reports of cytokine release syndrome, systemic toxicity, or serious immune-related AEs.
If these results are replicated in the Phase 3 OVATION 3 trial, it may result in transforming the standard of care for advanced ovarian cancer patients, where no improvement in OS has been reported in more than 25 years.
Financial Update
On August 5, 2025, Imunon announced financial results for the second quarter of 2025. As expected, the company did not report any revenue during the second quarter of 2025. R&D expenses in the second quarter of 2025 were $1.2 million compared to $2.8 million in the second quarter of 2024. The decrease was primarily due to lower costs associated with the OVATION 2 study, the Phase 1 PlaCCine DNA vaccine trial, and the development of the PlaCCine DNA vaccine technology. G&A expenses in the second quarter of 2025 were $1.5 million compared to $2.2 million for the first quarter of 2024. The decrease was primarily due to lower employee-related and legal expenses.
As of June 30, 2025, Imunon had approximately $4.7 million in cash and cash equivalents. During July 2025 the company received $3.1 million in net proceeds from the exercise of warrants and sales under the ATM facility. We estimate the company has sufficient capital to fund operations into the fourth quarter of 2025, however substantial additional capital will be necessary to complete the OVATION 3 trial. Following a 1-for-15 reverse split enacted on July 23, 2025, as of August 1, 2025 Imunon has approximatley 2.2 million common shares outstanding. The company also recently announced a stock dividend, whereby 0.15 shares of common stock will be granted per each share of common stock outstanding. This will result in the issuance of approximately 448,000 shares, which are payable to holders of record as of August 7, 2025. When factoring in stock options, warrants, and the stock dividend we estimate the company has a fully diluted share count of approximately 3.8 million.
Conclusion
We’re excited to see that Imunon has gotten the first patient dosed in the OVATION 3 trial and we look forward to updates from the company as the trial advances, including its efforts to secure financing for the study. The stock dividend is a nice reward for shareholders and shows the company is committed to making sure its interests align with those of current shareholders. We have adjusted our model to account for the reverse split and the July 2025 financing, and our valuation now stands at $45 per share.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
